Direxion Healthcare Bull 3X

Erasca and Merck Collaborate to Study ERAS-0015 Combined with KEYTRUDA for RAS-Mutant Solid Tumors

Eli Lilly Announces Positive Phase 3 Results for Retatrutide, Showing Significant Weight Loss in Obese Patients

Johnson & Johnson Partners with Abu Dhabi Health Services to Launch Global Open Surgical Intelligence Network

Eli Lilly's Retatrutide 12mg Dose Achieves 30.3% Average Weight Loss at 104 Weeks

Eli Lilly: Patients on Highest Dose of Retatrutide Achieve 28.3% Weight Loss

Johnson & Johnson's Nipocalimab Approved in China

J&J's Efgartigimod Alfa Approved by China NMPA for Generalized Myasthenia Gravis

National Advertising Review Board Refers Merck's Bravecto Dose Claim to FTC and FDA

Eli Lilly Acquires Engage Bio to Accelerate Non-Viral Gene Drug Development

Merck and Kailun Bio's Sac-TMT Succeeds in Phase III Endometrial Cancer Trial

CDD and Eli Lilly Collaborate to Integrate TuneLab AI Platform into CDD Vault

Trump Portfolio Precisely Trades UnitedHealth Before Medicare Policy Reversal

Fideuram Intesa Sanpaolo Acquires 84,300 JNJ Shares Worth $17.4M in Q4

Eli Lilly and Company announces an additional $4.5 billion investment in its Indiana manufacturing sites

Eli Lilly and Novo Nordisk are preparing to launch high-dose obesity treatments in the South Korean market

Financial disclosure reveals Donald Trump invested in Eli Lilly in Q1 2026, coinciding with the government's push for favorable weight-loss drug policies.

UnitedHealth Group Faces Profit Pressure Amid Rising Medical Costs and Membership Structure Changes

Eli Lilly Completes Key Drug Interaction Study for its KRAS Inhibitor, Olomorasib

New report shows Eli Lilly and Novo Nordisk dominate GLP-1 drug citations in AI tools

Lilly China Launches "Tuo Hu Chang An" Patient Assistance Program to Support IBD Patients

Agape ATP

PicoCELA

Co-Diagnostics

Tradr 2X Long QBTS Daily ETF

Tradr 2X Long RGTI Daily ETF

Defiance Daily Target 2X Long RGTI ETF

Netcapital

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

Akanda

NewGenIvf

Eagan-based Sieben Alexander, P.A. secured a $10.2 million jury verdict for Daniel Heyer and his wife against five cosmetic talc manufacturers, marking the second-largest mesothelioma personal injury award in Minnesota history. The jury found that the companies, including Vi-Jon LLC and Johnson & Johnson, sold dangerous products without warning consumers, leading to Mr. Heyer's cancer diagnosis at age 43. The case highlights the risks associated with asbestos-contaminated talc products.

prnewswire

Johnson & Johnson

Merck

Perrigo

09:41 ETSieben Alexander, P.A. Secures $10.2M Verdict for Twin Cities Family Against Cosmetic Talc Manufacturers

LLYX

ELIL

Eli Lilly's experimental weight-loss injection, retatrutide, demonstrated significant efficacy in a Phase 3 trial, with participants losing up to 28.3% of their body weight. Nearly half of the participants lost over 30%. This medication, which combines GIP, GLP-1, and glucagon, may rival bariatric surgery in effectiveness. Side effects included nausea and diarrhea, with some participants discontinuing due to these issues. Retatrutide is anticipated to enhance Lilly's obesity treatment portfolio.

Dow Jones

Eli Lilly

Defiance Daily Target 2X Long LLY ETF

Direxion Daily LLY Bull 2X Shares

Lilly's new experimental shot produced 28% weight loss

ELIS

LABU

Eli Lilly reported positive results from the Phase III TRIUMPH-1 trial for Retatrutide, showing significant weight loss in adults with obesity. At 80 weeks, participants lost an average of 64.4 pounds (25.9%) on the 9 mg dose and 70.3 pounds (28.3%) on the 12 mg dose. Additionally, 65.3% of those on the 12 mg dose achieved a BMI below 30. The drug also improved cardiovascular risk factors. Lilly shares closed at $1,018.87, down 0.25%.

rttnews

Proshares Ultra Nasdaq Biotech

Direxion Daily LLY Bear 1X Shares

iShares Biotechnology ETF

SPDR S&P Biotech

iShares US Pharma

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

Lilly Reports Positive Topline Data From Phase III Obesity Study Of Retatrutide

Johnson & Johnson has partnered with the Department of Health - Abu Dhabi to launch a global open surgical intelligence network, with Abu Dhabi as the first node. The initiative will integrate the Polyphonic digital ecosystem with the emirate’s health system, involving AWS and NVIDIA as technology partners. The platform aims to enhance AI development in surgical workflows by capturing high-fidelity surgical data across various hospitals.

PUBT

NVIDIA

NVIDIA Corporation

Johnson & Johnson partners with Abu Dhabi health regulator on global intelligent OR network

NVOX

Lower-priced oral obesity drugs from Novo Nordisk and Eli Lilly are attracting patients away from compounded GLP-1 medications, as reported by U.S. doctors. The oral Wegovy and Foundayo are priced similarly to compounded alternatives, making them more appealing, especially with inconsistent insurance coverage. While Wegovy benefits from established physician familiarity and cardiovascular data, Foundayo's convenience may help it gain market share. However, reimbursement issues remain a significant barrier for patient access to these treatments.

Pharmexec

Novo Nordisk AS

Defiance Daily Target 2X Long NVO ETF

Citigroup

CITIGROUP INC 6.250 NON CUM SER II PFD WI

<![CDATA[Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report ]]>

SHANGHAI, May 21 (Reuters) - Johnson & Johnson's ( JNJ ) nipocalimab has won approval in China, the U.S. drugmaker said on its WeChat social media account Thursday. (Reporting by Andrew Silver in Shanghai Editing by Tomasz Janowski)

Fidelity

Johnson & Johnson says nipocalimab approved in China

INCY

Eli Lilly has acquired Engage Biologics for up to $202 million, enhancing its capabilities in non-viral DNA delivery. Bristol Myers Squibb has partnered with Anthropic to implement the Claude platform across its operations, while Incyte expands its collaboration with Genesis Molecular AI, potentially exceeding $1 billion. Additionally, the FDA has granted two new indications for Enhertu in early-stage HER2-positive breast cancer, marking its entry into curative-intent treatment.

Bristol Myers Squibb

Incyte

Bristol-Myers Squibb Company

<![CDATA[Pharmaceutical Executive Daily: Eli Lilly Acquires Engage Bio]]>

Johnson & Johnson has partnered with the Department of Health in Abu Dhabi to create an open surgical intelligence network, enhancing AI in surgical procedures. This initiative positions Abu Dhabi as a leader in a global program aimed at revolutionizing surgery through AI technology, known as Polyphonic™.

Unusual Whales

Health Care Select Sector SPDR

VG Health

iShares Global Healthcare

SPDR S&P Health Equip

iShares US Medical Devices

Johnson && Johnson Advances Creation of Global Intelligent OR Network in collaboration with Department of Health - Abu Dhabi

ERAS

Erasca has partnered with Merck to study ERAS-0015 in combination with KEYTRUDA for RAS mutant solid tumors. This collaboration aims to reduce costs and enhance the drug's market position amid ongoing financial losses and legal challenges. Investors should monitor early trial results and funding strategies, as well as the resolution of patent disputes, which could impact the drug's future development and investor interest.

Simplywall

Erasca

Invesco Biotechnology & Genome ETF

Invesco Nasdaq Biotechnology ETF

Ark Genomic Revolution ETF

VanEck Biotech ETF

ALPS Medical Breakthrough

Amgen

Erasca Merck Pact Puts ERAS 0015 KEYTRUDA Combo In Investor Focus

Eli Lilly (NYSE: LLY) is acquiring Engage Biologics to enhance its genetic medicine capabilities and integrating AI/ML tools into the Collaborative Drug Discovery Vault platform. This strategy aims to expand beyond its GLP-1 focus on obesity and diabetes. Despite a 5.7% year-to-date decline, Lilly's stock has risen 41.5% over the past year. The new partnerships may increase R&D complexity but could also position Lilly favorably in genetic therapies and AI-driven collaborations, potentially influencing long-term market evaluations.

Viking Therap

Pfizer

Eli Lilly Broadens Genetic Medicine And AI Partnerships Beyond GLP‑1 Focus

Direxion Healthcare Bull 3X(CURE.US)